192P Human epididymis protein 4 as a predictor of response to neoadjuvant chemotherapy in epithelial ovarian cancer

Abstract

Neoadjuvant chemotherapy is the best option for most epithelial ovarian cancers as they present in stage III & IV.The important determinants of survival in ovarian cancer include complete cytoreduction and response to platinum based chemotherapy . HE4, a novel biomarker was found to be better predictor of optimal cytoreduction and platinum sensitivity compared to CA 125 which has low sensitivity and specificity in premenopausal women. This study is done to assess the role of serum marker HE4 in predicting response to chemotherapy in epithelial ovarian cancer.